Inactive Instrument
Taro Pharmaceutical Industries Ltd. Stock Other OTC
Stocks
IL0010827181
Pharmaceuticals
|
End-of-day quote
Other OTC
|
||
| - USD | - |
|
| 07-01 | FDA Grants Tentative Approval for ANDA 212581 Azelaic Acid Topical Foam | CI |
| 25/06/24 | Taro Pharmaceutical Industries Ltd.(NYSE:TARO) dropped from S&P Global BMI Index | CI |
| Manager | Title | Age | Since |
|---|---|---|---|
William Coote
DFI | Director of Finance/CFO | 71 | 01/12/2021 |
Richard Glaze
CTO | Chief Tech/Sci/R&D Officer | 60 | - |
Hagai Reingold
COO | Chief Operating Officer | - | 01/01/2002 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 69 | 01/09/2010 | |
James Kedrowski
BRD | Director/Board Member | 74 | 18/05/2011 |
| Chairman | 70 | 23/09/2010 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.70% | +0.73% | +51.95% | +115.39% | 1,056B | |
| -0.92% | -1.40% | +43.13% | +71.06% | 645B | |
| -0.12% | -0.85% | +13.51% | +77.29% | 465B | |
| -2.06% | -1.44% | +73.88% | +42.31% | 368B | |
| -0.06% | -3.88% | +34.32% | +40.74% | 335B | |
| -0.79% | +2.01% | +19.82% | +28.48% | 275B | |
| -1.19% | -1.21% | +9.82% | +12.15% | 255B | |
| -0.25% | +3.86% | +49.46% | +58.38% | 229B | |
| -1.03% | -1.12% | +34.85% | +102.00% | 188B | |
| Average | -0.81% | +0.12% | +36.75% | +60.86% | 423.98B | |
| Weighted average by Cap. | -0.97% | +0.30% | +40.22% | +72.41% |
Employees
-
Sector
Pharmaceuticals
Select your edition
All financial news and data tailored to specific country editions
